222 related articles for article (PubMed ID: 21663673)
1. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.
Datta A; Adelson ME; Mogilevkin Y; Mordechai E; Sidi AA; Trama JP
BMC Cancer; 2011 Jun; 11():234. PubMed ID: 21663673
[TBL] [Abstract][Full Text] [Related]
2. SiRNA knockdown of the DEK nuclear protein mRNA enhances apoptosis and chemosensitivity of canine transitional cell carcinoma cells.
Yamazaki H; Iwano T; Otsuka S; Kagawa Y; Hoshino Y; Hosoya K; Okumura M; Takagi S
Vet J; 2015 Apr; 204(1):60-5. PubMed ID: 25773167
[TBL] [Abstract][Full Text] [Related]
3. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
5. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
6. DEK Is a Potential Biomarker Associated with Malignant Phenotype in Gastric Cancer Tissues and Plasma.
Lee KF; Tsai MM; Tsai CY; Huang CG; Ou YH; Hsieh CC; Hsieh HL; Wang CS; Lin KH
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766266
[TBL] [Abstract][Full Text] [Related]
7. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
8. DEK: A novel early screening and prognostic marker for breast cancer.
Ying G; Wu Y
Mol Med Rep; 2015 Nov; 12(5):7491-5. PubMed ID: 26459608
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
10. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Lee SY; Jung W; Lee J; Kim A; Kim HK; Kim BH
Histol Histopathol; 2019 Nov; 34(11):1279-1288. PubMed ID: 31066459
[TBL] [Abstract][Full Text] [Related]
11. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
12. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.
Vlahou A; Schellhammer PF; Mendrinos S; Patel K; Kondylis FI; Gong L; Nasim S; Wright GL
Am J Pathol; 2001 Apr; 158(4):1491-502. PubMed ID: 11290567
[TBL] [Abstract][Full Text] [Related]
14. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.
Lin L; Piao J; Gao W; Piao Y; Jin G; Ma Y; Li J; Lin Z
BMC Cancer; 2013 Jul; 13():366. PubMed ID: 23902796
[TBL] [Abstract][Full Text] [Related]
15. High expression of DEK predicts poor prognosis of gastric adenocarcinoma.
Piao J; Shang Y; Liu S; Piao Y; Cui X; Li Y; Lin Z
Diagn Pathol; 2014 Mar; 9():67. PubMed ID: 24650035
[TBL] [Abstract][Full Text] [Related]
16. High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer.
Wang X; Lin L; Ren X; Lin Z; Li Z; Li C; Jin T
Int J Clin Exp Pathol; 2014; 7(8):5016-23. PubMed ID: 25197373
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder.
Srivastava AK; Singh PK; Singh D; Dalela D; Rath SK; Goel MM; Bhatt ML
Tumour Biol; 2014 Aug; 35(8):8243-8. PubMed ID: 24852426
[TBL] [Abstract][Full Text] [Related]
18. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.
Retz M; Lehmann J; Amann E; Wullich B; Röder C; Stöckle M
J Urol; 2003 Jan; 169(1):86-9. PubMed ID: 12478110
[TBL] [Abstract][Full Text] [Related]
19. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract][Full Text] [Related]
20. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma.
Bialkowska-Hobrzanska H; Bowles L; Bukala B; Joseph MG; Fletcher R; Razvi H
Mol Diagn; 2000 Dec; 5(4):267-77. PubMed ID: 11172490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
